Concepts and challenges in quantitative pharmacology and model-based drug development

AAPS Journal

Volumn 10, Issue 4, 2008, Pages 552-559

  Zhang, Liping ^a   Pfister, Marc ^a   Meibohm, Bernd ^b  

^a BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Drug development; Modeling; Pharmacodynamics; Pharmacokinetics; Pharmacometrics; Simulation

Indexed keywords

ANALYTIC METHOD; ARTICLE; CONCEPT ANALYSIS; CONCEPTUAL FRAMEWORK; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG INFORMATION; DRUG RESEARCH; DRUG SCREENING; METHODOLOGY; MONTE CARLO METHOD; PATIENT CARE; PHARMACEUTICAL CARE; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOLOGICAL PARAMETERS; POSTMARKETING SURVEILLANCE; QUANTITATIVE ANALYSIS; QUANTITATIVE STUDY; STANDARDIZATION; STOCHASTIC MODEL; BIOLOGICAL MODEL; BLOOD ANALYSIS; CLINICAL TRIAL; COMPUTER SIMULATION; FINANCIAL MANAGEMENT; HUMAN; PHARMACOLOGY; THEORETICAL MODEL;

DRUG;

BLOOD CHEMICAL ANALYSIS; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MARKETING OF HEALTH SERVICES; MODELS, BIOLOGICAL; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY;

EID: 65549156693     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-008-9062-3     Document Type: Article

References (42)

1. Congressional Budget Office. A CBO Study: Research and Development in the Pharmceutical Industry, The Congress of the United States, Washington, DC, 2006.
2. I. Kola, and J. Landis. Can the pharmaceutical industry reduce attrition rates. Nat. Rev. Drug Discov. 3:711-715 (2004).
3. S. Arlington, S. Barnett, S. Hughes, and J. Palo. Pharma 2010: The Threshold to Innovation, IBM Business Consulting Services, Somers, 2002.
4. S. Frantz. Pipeline problems are increasing the urge to merge. Nat. Rev. Drug Discov. 5:977-979 (2006).
5. Tufts Center for the Study of Drug Development. Impact Report: Fastest drug developers consistently best peers on key performance metrics, Tufts University, Boston, 2006.
6. Center for Drug Evaluation and Research. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products, US Food and Drug Administration, Rockville, 2004.
7. C. Csajka, and D. Verotta. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J. Pharmacokinet. Pharmacodyn. 33: 227-279 (2006).
8. V. A. Bhattaram, B. P. Booth R. P. Ramchandani et al. Impact of pharmacometrics on drug approval and labeling decisions: A survey of 42 new drug applications. Aaps J. 7:E503-E512 (2005).
9. D. D. Breimer, and M. Danhof. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe" paradigm. Clin. Pharmacokinet. 32:259-267 (1997).
10. J. Y. Chien, S. Friedrich, M. A. Heathman, D. P. de Alwis, and V. Sinha. Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation. Aaps J. 7:E544-E559 (2005).
11. B. Meibohm, and H. Derendorf. Pharmacokinetic/pharmacodynamic studies in drug product development. J. Pharm. Sci. 91:18-31 (2002).
12. S. C. Olson, H. Bockbrader, R. A. Boyd, J. Cook, J. R. Koup, R. L. Lalonde, P. H. Siedlik, and J. R. Powell. Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: Experience at Parke-Davis. Clin. Pharmacokinet. 38:449-459 (2000).
13. B. G. Reigner, P. E. Williams, I. H. Patel, J. L. Steimer, C. Peck, and P. van Brummelen. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin. Pharmacokinet. 33: 142-152 (1997).
14. L. B. Sheiner. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61:275-291 (1997).
15. J. S. Barrett, M. J. Fossler, K. D. Cadieu, and M. R. Gastonguay. Pharmacometrics: A multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J. Clin. Pharmacol. 48:632-649 (2008).
16. K. Gough, M. Hutchison, O. Keene, B. Byrom, S. Ellis, L. Lacey, and J. McKellar. Assessment of dose proportionality: Report from the statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party. Drug Inf. J. 29:1039-1048 (1995).
17. H. Derendorf, and B. Meibohm. Modeling of pharmacokinetic/ pharmacodynamic (PK-PD) relationships: Concepts and perspectives. Pharm Res. 16:176-185 (1999).
18. L. B. Sheiner, and J. L. Steimer. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu. Rev. Pharmacol. Toxicol. 40:67-95 (2000).
19. L. Zhang, V. Sinha, S. T. Forgue, S. Callies, L. Ni, R. Peck, and S. R. Allerheiligen. Model-based drug development: The road to quantitative pharmacology. J. Pharmacokinet. Pharmacodyn. 33:369-393 (2006).
20. R. Krishna. Quantitative clinical pharmacology: Making paradigm shifts a reality. J. Clin. Pharmacol. 46:966-967 (2006).
21. T. H. Grasela, J. Fiedler-Kelly, C. A. Walawander, J. S. Owen, B. B. Cirincione, K. E. Reitz, E. A. Ludwig, J. A. Passarell, and C. W. Dement. Challenges in the transition to model-based development. Aaps J. 7:E488-E495 (2005).
22. E. A. Wintner, and C. C. Moallemi. Quantized surface complementarity diversity (QSCD): A model based on small molecule-target complementarity. J. Med. Chem. 43:1993-2006 (2000).
23. B. Schoeberl, U. B. Nielsen, and R. Paxson. Model-based design approaches in drug discovery, a parallel to traditional engineering approaches. IBS J. Res Dev. 50:645-653 (2006).
24. P. Arce, and M. Aznar. Modeling of phase equilibirum of binary mixtures composed by polystyrene and chlorofluorocarbons, hydrochlorofluorocarbons, hydrofluorocarbons and supercritical fluids using cubic and non-cubic equations of state. J. Supercrit. Fluids. 42:134-145 (2008).
25. A. Roncaglioni, and E. Benfenati. In silico-aided prediction of biological properties of chemicals: Oestrogen receptor-mediated effects. Chem. Soc. Rev. 37:441-450 (2008).
26. M. Pfister, N. E. Martin, L. P. Haskell, and J. S. Barrett. Optimizing dose selection with modeling and simulation: Application to the vasopeptidase inhibitor M100240. J. Clin. Pharmacol. 44:621-631 (2004).
27. B. Garcia-Mora, C. Santamaria, G. Rubio, and J. Luis Pontones. Modeling the recurrence-progression process in bladder carcinoma. Comput. Math Appl. 53:619-630 (2008).
28. K. Larsen, K. E. Hvass, T. B. Hansen, P. B. Thomsen, and K. Soballe. Effectiveness of accelerated perioperative care and rehabilitation intervention compared to current intervention after hip and knee arthroplasty. A before-after trial of 247 patients with a 3-month follow-up. BMC Musculoskelet. Disord. 9:59 (2008).
29. L. A. Kenna, L. Labbe, J. S. Barrett, and M. Pfister. Modeling and simulation of adherence: Approaches and applications in therapeutics. Aaps J. 7:E390-E407 (2005).
30. M. A. Koopmanschap, J. N. van Exel, B. van den Berg, and W. B. Brouwer. An overview of methods and applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics. 26:269-280 (2008).
31. R. L. Lalonde, K. G. Kowalski M. M. Hutmacher et al. Model-based drug development. Clin. Pharmacol. Ther. 82:21-32 (2007).
32. D. Stanski. Model-based drug development: A critical path opportunity. http://www.fda.gov/oc/initiatives/criticalpath/stanski/stanski.html (accessed 8/13/08).
33. P. Chaikin, G. R. Rhodes, R. Bruno, S. Rohatagi, and C. Natarajan. Pharmacokinetics/pharmacodynamics in drug development: An industrial perspective. J. Clin. Pharmacol. 40:1428-1438 (2000).
34. T. H. Grasela, C. W. Dement, O. G. Kolterman, M. S. Fineman, D. M. Grasela, P. Honig, E. J. Antal, T. D. Bjornsson, and E. Loh. Pharmacometrics and the transition to model-based development. Clin. Pharmacol. Ther. 82:137-142 (2007).
35. L. J. Lesko. Paving the critical path: How can clinical pharmacology help achieve the vision? Clin. Pharmacol. Ther. 81:170-177 (2007).
36. S. C. D. Johnson. The role of simulation in the managememnt of research: What can the pharmaceutical industry leanr from the aerospace industry? Drug Inf. J. 32:961-969 (1998).
37. C. A. O'Reilly, and M. L. Tushman. Winning through innovation: A practical guide to leading organizational change and renewal, Harvard Business School Press, Boston, 2002.
38. P. M. Senge, B. Smith, S. Schley, and N. Kruschwitz. The necessary revolution: How individuals and organisations are working together to create a sustainable world, Doubleday Business, New York, 2008.
39. V. A. Bhattaram, C. Bonapace D. M. Chilukuri et al. Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin. Pharmacol. Ther. 81:213-221 (2007).
40. C. Veyrat-Follet, R. Bruno, R. Olivares, G. R. Rhodes, and P. Chaikin. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin. Pharmacol. Ther. 68:677-687 (2000).
41. Y. Wang, A. V. Bhattaram, P. R. Jadhav, L. J. Lesko, R. Madabushi, J. R. Powell, W. Qiu, H. Sun, D. S. Yim, J. J. Zheng, and J. V. Gobburu. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: Impact of FDA pharmacometrics during 2004-2006. J. Clin. Pharmacol. 48:146-156 (2008).
42. R. Miller, W. Ewy, B. W. Corrigan, D. Ouellet, D. Hermann, K. G. Kowalski, P. Lockwood, J. R. Koup, S. Donevan, A. El-Kattan, C. S. Li, J. L. Werth, D. E. Feltner, and R. L. Lalonde. How modeling and simulation have enhanced decision making in new drug development. J. Pharmacokinet. Pharmacodyn. 32:185-197 (2005).